"I've repeatedly gravitated to the hardest problems in organizations and untangled them"
I think he considers traffic to the website a problem to be rid of.
LOL. Yahoo is distraught with poor project management and subsequent QC before launch.
I would expect it to be highly accurate then. They know what biomarker to look for for specific issue.
I'm not a medical doctor but I'd say that it's highly dependent on what you want to look for. Once in the urine, you cannot be guaranteed that's it's in an identifiable form; but in most cases in just might be.
Do they follow up with a blood biopsy if the urine produces and unusual profile?
Their website does not reflect this but looking on clinicaltrials, they do have a P3. I'll have to consider it more closely.
interesting company. Nothing in P3 but have varlilumab opdivo combo. I think you're in for a long wait there. If they score a collaboration, I might get in. I won't touch it until well into P3 and after I study it more after they hit P3 and I see some publications from the P2 trials.
It's in a trial with sunitinib atm. There is a fair chance that which ever is inferior ( cf. Opdivo ) will quickly replace sunitinib.
Curious. It looks like it may be a good thing but I'm having trouble with the fact that their trigger was early april and they've still not released the analysis or any analysis. Then they presented only the P2 data at ASCO in early June...
What is your take on that?
The EMA post today shows that Cabo is in line for "centralised marketing authorisation".
Wilder is likely correct in his theory of the labeling holding things back given no official announcement and the UAE officially adopted Cabo for RCC secondline. Looks like they're just waiting on the label.
The EMA decision on Cabo for RCC is expected in September. Thus my post on "september".
Check the clinicaltrials gov site for those two drugs and you'll see the trial. There is a phase 1 trial with the following listed:
Malignant Reproductive System Neoplasm; Malignant Urinary System Neoplasm; Metastatic Urethral Neoplasm; Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter; Progressive Neoplastic Disease; Recurrent Bladder Carcinoma; Recurrent Urethra Carcinoma; Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter; Regional Urothelial Carcinoma of the Renal Pelvis and Ureter; Solid Neoplasm; Stage III Bladder Urothelial Carcinoma; Stage III Urethral Cancer; Stage IV Bladder Urothelial Carcinoma; Stage IV Urethral Cancer; Urethral Urothelial Carcinoma
I guess it's up to you to decide on the level of accuracy of an article which is not a press release by the company.
"En effet, l’EMA prépare actuellement une revue sur une probable entrée de Cabozantinib sur le marché britannique (réponse attendue en septembre 2016), dans le cadre du traitement du cancer du rein en deuxième intention."
Indeed, the EMA is preparing a review on Cabozantinib entry likely in the UK market ( response expected in September 2016) , in the second line treatment for kidney cancer.